Soft tissue allograft market seen reaching $6.97 billion by 2030

The Business Research Company says the soft tissue allograft market will grow from $5.24 billion in 2026 to $6.97 billion by 2030, led by demand for minimally invasive procedures, joint reconstruction and sports medicine. North America held the largest share in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Soft tissue allografts are increasingly used in orthopedic and reconstructive surgery when a patient’s own tissue is not enough or not available. - The market’s projected growth signals rising demand for donor-derived tissue solutions across hospitals, sports medicine and transplant programs. - The report points to a larger shift toward less invasive procedures, faster recovery and broader use of tissue banking.

What happened: - The Business Research Company projected the global soft tissue allograft market will rise from $5.24 billion in 2026 to $6.97 billion by 2030. - The forecast implies a 7.4% compound annual growth rate from 2026 to 2030. - The company estimated the market at $4.87 billion in 2025. - The market grew at a 7.7% CAGR from 2025 to 2026, according to the report. - The report was released Aug. 30, 2026. - Download a free sample of the report. - View the full market report.

The details: - Soft tissue allografts use tissue transplanted from human donors to repair, replace or strengthen damaged soft tissues. - The grafts provide structural support and help healing when native tissue is insufficient. - The report ties recent growth to orthopedic injuries, sports-related surgeries, greater donor tissue availability, better sterilization techniques and more hospital-based transplant programs. - Future growth drivers include an aging population, more joint reconstruction surgeries, expansion of sports medicine, better tissue preservation methods and standardized regulatory frameworks. - The report highlights rising use of orthopedic reconstruction procedures, sports medicine allografts, sterilized tissue processing, minimally invasive grafting techniques and hospital-centric tissue banking. - Minimally invasive procedures are growing because they can reduce trauma, pain, complications and recovery time. - The American Society of Plastic Surgeons reported a 7% increase in minimally invasive procedures in 2023, outpacing traditional surgery growth by 2%. - Neuromodulator injections topped 9 million procedures, and hyaluronic acid fillers exceeded 5 million procedures, according to the same update. - North America held the largest market share in 2025. - Asia-Pacific is forecast to be the fastest-growing region in the coming years. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The forecast suggests soft tissue allografts are benefiting from two demand pools at once: more orthopedic need from aging populations and more elective use in sports and aesthetic-related procedures. - The emphasis on sterilized processing and regulatory frameworks suggests buyers may increasingly favor standardized supply chains and consistent tissue quality. - The regional split shows mature markets still dominate today, while faster growth is shifting toward regions with expanding healthcare access and investment in regenerative medicine.

What’s next: - The market is expected to keep expanding through 2030 if demand for minimally invasive surgery and joint reconstruction continues to rise. - Growth in Asia-Pacific may accelerate as tissue banking and regenerative medicine investments broaden access. - The report package includes market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards, hotspot infographics and updated graphics and tables. - The Business Research Company provided contact details for expert follow-up through Saumya Sahay and its marketing channels.